Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

422 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prevalence and predictors of deterioration of a trustful patient-provider relationship among HIV-infected persons treated with antiretroviral therapy.
Préau M, Leport C, Villes V, Michelet C, Collin F, Carrieri MP, Ragnaud JM, Taieb A, Raffi F, Spire B; ANRS CO-8 APROCO Study Group. Préau M, et al. Among authors: leport c. J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):467-71. doi: 10.1097/qai.0b013e31815f3bdc. J Acquir Immune Defic Syndr. 2008. PMID: 18434958
Factors associated with nonadherence to highly active antiretroviral therapy: a 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase.
Carrieri MP, Leport C, Protopopescu C, Cassuto JP, Bouvet E, Peyramond D, Raffi F, Moatti JP, Chêne G, Spire B. Carrieri MP, et al. Among authors: leport c. J Acquir Immune Defic Syndr. 2006 Apr 1;41(4):477-85. doi: 10.1097/01.qai.0000186364.27587.0e. J Acquir Immune Defic Syndr. 2006. PMID: 16652057
Prolonged medically recorded treatment interruptions among HIV-infected patients on highly active antiretroviral therapy with controlled viremia: when physicians have to juggle patient negotiation and guidelines.
Protopopescu C, Roux P, Carrieri MP, Katlama C, Collin F, Besnier JM, Chêne G, Raffi F, Spire B, Leport C; ANRS CO8 APROCO-COPILOTE Study Group. Protopopescu C, et al. Among authors: leport c. J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):544-6. doi: 10.1097/QAI.0b013e3181ba1c48. J Acquir Immune Defic Syndr. 2010. PMID: 20220376 No abstract available.
Health-related quality of life after 1 year of highly active antiretroviral therapy.
Carrieri P, Spire B, Duran S, Katlama C, Peyramond D, François C, Chêne G, Lang JM, Moatti JP, Leport C; APROCO Study Group. Carrieri P, et al. Among authors: leport c. J Acquir Immune Defic Syndr. 2003 Jan 1;32(1):38-47. doi: 10.1097/00126334-200301010-00006. J Acquir Immune Defic Syndr. 2003. PMID: 12514412 Clinical Trial.
Plasma levels of indinavir and nelfinavir at time of virologic response may have a different impact on the risk of further virologic failure in HIV-infected patients.
Le Moing V, Peytavin G, Journot V, Cottalorda J, Bouvet E, Chêne G, Préau M, de Boever CM, Leport C, Raffi F; Antiprotease Cohort (APROCO) Study Group. Le Moing V, et al. Among authors: leport c. J Acquir Immune Defic Syndr. 2003 Dec 15;34(5):497-9. doi: 10.1097/00126334-200312150-00008. J Acquir Immune Defic Syndr. 2003. PMID: 14657760
HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population.
Lewden C, Chene G, Morlat P, Raffi F, Dupon M, Dellamonica P, Pellegrin JL, Katlama C, Dabis F, Leport C; Agence Nationale de Recherches sur le Sida et les Hepatites Virales (ANRS) CO8 APROCO-COPILOTE Study Group; Agence Nationale de Recherches sur le Sida et les Hepatites Virales (ANRS) CO3 AQUITAINE Study Group. Lewden C, et al. Among authors: leport c. J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):72-7. doi: 10.1097/QAI.0b013e318134257a. J Acquir Immune Defic Syndr. 2007. PMID: 17621240 Free article.
422 results